For research use only. Not for therapeutic Use.
Prasugrel-d3 (CAS: 1127253-02-4), a premium pharmaceutical research compound designed for advanced cardiovascular and antiplatelet studies. As a deuterated analog of Prasugrel, it offers enhanced stability and improved pharmacokinetic properties. Prasugrel-d3 is ideal for use in pharmacological and biochemical research, providing precise and reliable data for your studies. This high-purity compound ensures consistent results, aiding in the development of novel therapies for thrombotic cardiovascular events. Trusted by leading laboratories, Prasugrel-d3 is your go-to solution for cutting-edge cardiovascular research. Unlock new possibilities in antiplatelet therapy with Prasugrel-d3, where innovation meets reliability.
| Catalog Number | S000185 |
| CAS Number | 1127253-02-4 |
| Molecular Formula | C20H17D3FNO3S |
| Purity | ≥95% |
| Target | P2Y Receptor |
| IUPAC Name | [5-[2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl]-6,7-dihydro-4H-thieno[3,2-c]pyridin-2-yl] 2,2,2-trideuterioacetate |
| InChI | InChI=1S/C20H20FNO3S/c1-12(23)25-18-10-14-11-22(9-8-17(14)26-18)19(20(24)13-6-7-13)15-4-2-3-5-16(15)21/h2-5,10,13,19H,6-9,11H2,1H3/i1D3 |
| InChIKey | DTGLZDAWLRGWQN-FIBGUPNXSA-N |
| SMILES | [2H]C([2H])([2H])C(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4 |
| Reference | [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216. [2]. Wijeyeratne YD, et al. Anti-platelet therapy: ADP receptor antagonists. Br J Clin Pharmacol. 2011 Oct;72(4):647-57. [3]. Sugidachi A, et al. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel’s active metabolite. J Thromb Haemost. 2007 Jul;5(7):1545-51. |
